다가오는 결정
날짜가 잡힌 것만 · 가까운 순서이 화면은 바이오 종목을 볼 때 챙길 일정과 허가 기록을 한곳에 모아요. 맨 위에는 날짜가 잡힌 FDA 자문위 회의와 임상 1차 완료 예정일이, 아래에는 식약처 품목허가와 FDA 승인, 국내외 임상의 최근 갱신이 있어요.This page gathers the dates and approval records worth tracking for biotech stocks. At the top are scheduled FDA advisory committee meetings and planned trial primary completions; below are Korean MFDS permits, FDA approvals and recent trial updates in Korea and abroad.
서울 날짜로 11월 17일 기준, 이 목록에는 앞으로 180일 안에 날짜가 잡힌 항목이 14건 있어요. 자문위 회의 1건, 임상 1차 완료 예정 13건이고, 가장 가까운 것은 11월 19일 FDA 자문위 회의예요.As of Nov 17 in Seoul, the list holds 14 dated items in the next 180 days: 1 advisory committee meeting and 13 planned trial primary completions. The nearest, dated Nov 19, is an FDA advisory committee meeting.
- 11월 19일D-2AI 요약의료기기 자문위 미생물학 분과 · 병원체 무관 염기서열 분석Microbiology Devices Panel of the Medical Devices Advisory Committee
- 11월 25일D-8AI 요약만성 면역혈소판감소증 성인 · 릴자브루티닙 단독 투여
릴자브루티닙은 면역 반응을 조절하는 경구 신약 후보예요. 일본 3상을 마친 환자에게 치료를 이어가는 연장 연구예요.
3상진행 중(모집 종료)대상 3명 - 12월 3일D-16AI 요약전이성 호르몬 민감성 전립선암 남성 · JSB462와 아비라테론 병용
JSB462는 개발 코드명 약물이고, 아비라테론은 전립선암 승인 약물이에요. 이 2상 공개표지 시험은 두 약을 함께 썼을 때 효과와 안전성을 살펴봐요.
2상진행 중(모집 종료)대상 168명 - 12월 23일D-36AI 요약중증 호산구성 천식 소아 환자 · 벤랄리주맙 대 위약
벤랄리주맙은 호산구를 줄여 천식 발작을 막는 승인된 약물이에요. 이 3상 위약 대조 시험은 소아에서 발작 예방 효과를 확인하는 단계예요.
3상진행 중(모집 종료)대상 94명 - 12월 23일D-36AI 요약16~75세 원발성 국소분절사구체경화증 또는 미세변화질환 · 프렉살리맙, 브리베키맙, 릴자부루티닙 비교
세 약은 모두 개발 중인 약물이에요. 이 2상은 신장 질환인 사구체 질환에서 각 약물의 효과와 안전성을 살펴봐요.
2상모집 중대상 84명 - 1월 6일D-50AI 요약전신경화증(강피증) 환자 · 아니프롤루맙 대 위약 이중맹검 및 공개 표지 투여 평가
아니프롤루맙은 면역 반응을 조절하는 항체 약물이에요. 3상 이중맹검 위약 대조 시험은 환자와 의료진 모두 투여 내용을 모르는 상태에서 효과를 비교하는 단계예요.
3상진행 중(모집 종료)대상 314명 - 2027-02 중D-76
- 2월 4일D-79
- 2월 22일D-97AI 요약이상지질혈증 · AZD0780 단독 또는 로수바스타틴 용량별 병용 대 위약 비교
AZD0780은 개발 코드명 약물이에요. 2/3상 시험은 콜레스테롤 저하 효과와 안전성을 위약 및 기존 약물과 비교해 확인해요.
2·3상진행 중(모집 종료)대상 432명 - 4월 8일D-142
- 4월 26일D-160
- 5월 2일D-166
- 5월 10일D-174AI 요약기존 심혈관 질환 환자 · 인클리시란 300mg 대 위약, 심혈관 사건 예방 평가
인클리시란은 LDL 콜레스테롤을 낮추도록 간에서 작용하는 siRNA 계열 약물이에요. 3상 위약 대조 시험은 심혈관 사건을 줄이는지 위약과 비교해 확인하는 단계예요.
3상진행 중(모집 종료)대상 17,004명 - 5월 12일D-176AI 요약과체중·비만·제2형 당뇨병 · 카그릴린타이드 · 위약 대조
개발 코드 약물로, 3상 시험은 허가 신청 전 효능을 최종 확인하는 단계예요.
3상진행 중(모집 종료)대상 330명
이 화면 읽는 법How to read this page
- 임상 1차 완료 예정일은 확정일이 아니라 계획일이에요. 스폰서가 자주 고치고, 1차 완료는 결과 발표일이 아니에요. 자문위 회의일은 Federal Register 공고 날짜예요. 등록·허가 기록은 임상 결과나 허가 가능성을 말하지 않아요. 허가 뒤 주가는 '허가 그 후'에서 따로 기록해요.A trial's primary completion date is a plan, not a fixed date. Sponsors revise it often, and primary completion is not a results date. A meeting's date is the one in its Federal Register notice. Registry and approval records say nothing about trial results or the odds of approval. Share prices after a Korean permit are recorded separately under After the permit.
- 임상은 워치리스트 스폰서 34곳의 등록 건 가운데 최근 14일 안에 갱신된 중재 2·3상이에요. 지금 목록의 임상 13건 가운데 7건이 90일 안에 1차 완료 예정이에요.The trials are interventional Phase 2/3 registrations of the 34 watchlist sponsors, updated in the last 14 days. Of the 13 trials listed now, 7 are due for primary completion within 90 days.
- 식약처 최근 품목허가는 2026-10-18부터 2026-11-16까지 115건이에요. 허가 62건, 신고 53건이고, '주목'은 허가된 전문의약품이나 신약·희귀의약품만 골라 보여 줘요.Recent MFDS permits hold 115 items from 2026-10-18 to 2026-11-16: 62 permits and 53 notifications. The Notable filter keeps permitted prescription drugs, new drugs and rare-disease drugs.
- FDA 최근 승인은 2026-09-17부터 2026-11-16까지의 원 신청 승인이에요. 신약(NDA) 22건과 바이오의약품(BLA) 6건은 한 줄씩, 제네릭(ANDA) 89건은 건수만 보여 줘요.Recent FDA approvals are original applications approved from 2026-09-17 to 2026-11-16: 22 new drug (NDA) and 6 biologic (BLA) approvals have a line each, and 89 generic (ANDA) approvals are only counted.
- AI 표시가 붙은 한 줄은 AI가 등록 원문이나 허가 정보를 읽고 쉬운 말로 줄인 거예요. 약 이름이나 임상·회의 제목을 누르면 ClinicalTrials.gov, 식약처, FDA, Federal Register의 원래 기록으로 가요.A line marked AI is a plain-words summary an AI wrote from the registry or approval record. Each drug name, trial title or meeting title opens the original record at ClinicalTrials.gov, the MFDS, the FDA or the Federal Register.
자료: ClinicalTrials.gov와 Federal Register는 6시간마다, openFDA와 식약처 의약품 허가정보(공공데이터포털)는 하루 한 번 받아 오고, 화면은 15분마다 다시 읽어요. 허가 뒤 주가는 금융위원회 공식 종가로 매겨요. 1차 완료 예정일FDA 자문위원회미국 신약 신청(NDA · BLA)AI 요약을 쓰는 기준Sources: ClinicalTrials.gov and the Federal Register are fetched every six hours, openFDA and the MFDS drug permit data (data.go.kr) once a day, and the page reads them again every 15 minutes. Prices after a Korean permit use the Financial Services Commission's official closes. Primary completion dateFDA advisory committeeUS drug applications (NDA · BLA)How AI summaries are kept
한국
식약처 허가 · 국내 스폰서 임상식약처 최근 품목허가
MFDS · DATA.GO.KR- 11월 13일
- 11월 13일
- 11월 12일
- 11월 12일
- 11월 11일
- 11월 11일
- 11월 11일
- 11월 10일
- 11월 10일
- 11월 10일
- 11월 10일
- 11월 10일
- 11월 9일
- 11월 9일
- 11월 9일
- 11월 6일
- 11월 5일
- 11월 4일
- 11월 4일
- 11월 4일
- 11월 3일
- 11월 3일
- 11월 3일
- 11월 3일
- 11월 3일
- 10월 30일
- 10월 30일
- 10월 30일
- 10월 30일
- 10월 30일
- 10월 30일
- 10월 30일
- 10월 29일
- 10월 29일
- 10월 29일
- 10월 29일
- 10월 28일
- 10월 27일
- 10월 27일
- 10월 26일
- 10월 26일
- 10월 23일
- 10월 23일유티프씨주(주)유바이오로직스
AI 요약살모넬라 장티푸스균에 의한 장티푸스를 예방하는 주사제
전문의약품허가정제브이아이다당류-디프테리아CRM197(재조합)단백질접합체(균주: S. typhi NC08385),(숙주: E. coli BL21(DE3),벡터: pET-24a(+)) - 10월 23일
- 10월 23일
- 10월 23일
- 10월 22일
- 10월 22일
- 10월 22일
- 10월 20일
- 10월 20일
- 10월 20일
- 10월 20일
- 10월 20일
- 10월 19일
- 10월 19일
더 보기: 허가 후 주가 추적 · 국내 스폰서 임상한국 바이오 더 보기허가 후 주가 추적 · 국내 스폰서 임상
허가 그 후 — 주가 추적
MFDS × FSC · 자동 채점| 허가일 | 품목명 | 업체 | 기준가 | 현재(참고) | +1개월 | +3개월 | +6개월 |
|---|---|---|---|---|---|---|---|
| 2026-11-13 | 영진나프록센연질캡슐 | 영진약품(주) | 795원 | — | — | — | — |
| 2026-11-13 | 장듀오캡슐 | (주)종근당바이오 | 11,120원 | — | — | — | — |
| 2026-11-13 | 신신리쥬덤피디알엔크림(폴리데옥시리보뉴클레오티드나트륨) | 신신제약(주) | 3,890원 | — | — | — | — |
| 2026-11-13 | 페노핍엔정145밀리그램(페노피브레이트) | 동국제약(주) | 23,900원 | — | — | — | — |
| 2026-11-12 | 센스젤라크림(아젤라산) | 동국제약(주) | 24,800원 | −3.6% | — | — | — |
| 2026-11-12 | 지씨웰빙나이아신주(나이아신) | (주)녹십자웰빙 | 9,150원 | −3.8% | — | — | — |
| 2026-11-12 | 엠지픽연질캡슐 | (주)알피바이오 | 5,130원 | −2.5% | — | — | — |
| 2026-11-12 | 하이도네듀오정10/20밀리그램(도네페질염산염수화물,메만틴염산염) | (주)테라젠이텍스 | 2,070원 | −1.0% | — | — | — |
| 2026-11-11 | 아젤퓨어크림(아젤라산) | 일동제약(주) | 12,920원 | −2.7% | — | — | — |
| 2026-11-11 | 페노렉신정145밀리그램(페노피브레이트) | 안국약품(주) | 9,370원 | +1.7% | — | — | — |
| 2026-11-11 | 오코돈서방정10밀리그램(옥시코돈염산염)(수출용) | 하나제약(주) | 8,200원 | +1.2% | — | — | — |
| 2026-11-11 | 오코돈서방정20밀리그램(옥시코돈염산염)(수출용) | 하나제약(주) | 8,200원 | +1.2% | — | — | — |
| 2026-11-10 | 아젤릭스크림(아젤라산) | 경남제약(주) | 1,502원 | −1.3% | — | — | — |
| 2026-11-10 | 코앤원큐연질캡슐 | 동아제약(주) | 89,100원 | −1.0% | — | — | — |
| 2026-11-10 | 삼아코비안포르테정 | 삼아제약(주) | 12,840원 | +1.4% | — | — | — |
| 2026-11-10 | 히트플랜주(히알루론산나트륨) | (주)동구바이오제약 | 3,395원 | −0.3% | — | — | — |
| 2026-11-10 | 하나타우로리딘주2% | 하나제약(주) | 8,260원 | +0.5% | — | — | — |
| 2026-11-10 | 타우리딘주2%(타우로리딘) | (주)바스칸바이오제약 | 3,210원 | +11.7% | — | — | — |
| 2026-11-09 | 임팩타민프라임샷액 | (주)대웅제약 | 101,600원 | +0.3% | — | — | — |
| 2026-11-09 | 임팩타민에이플러스샷액 | (주)대웅제약 | 101,600원 | +0.3% | — | — | — |
| 2026-11-09 | 알셉틴듀오정10/20밀리그램(도네페질염산염수화물,메만틴염산염) | 알리코제약(주) | 1,750원 | +9.7% | — | — | — |
| 2026-11-09 | 아이코드베타연질캡슐 | (주)서흥 | 17,700원 | −9.2% | — | — | — |
| 2026-11-09 | 타스젯정1/10밀리그램(피타바스타틴칼슘, 에제티미브) | 위더스제약(주) | 6,560원 | −1.2% | — | — | — |
| 2026-11-06 | 하이드로퀸크림(히드로퀴논) | (주)에이프로젠바이오로직스 | 1,291원 | +1.2% | — | — | — |
| 2026-11-06 | 화이투벤키즈노즈시럽 | 동화약품(주) | 5,150원 | +4.3% | — | — | — |
| 2026-11-05 | 테라젠타우로리딘주2% | (주)테라젠이텍스 | 1,988원 | +3.1% | — | — | — |
| 2026-11-05 | 동아제약비스카르현탁액 | 동아제약(주) | 89,300원 | −1.2% | — | — | — |
| 2026-11-04 | 로베타존정0.5밀리그램(로베글리타존황산염) | 신풍제약(주) | 8,370원 | −5.4% | — | — | — |
| 2026-11-04 | 히디아리뉴겔(히알루론산나트륨) | 동아제약(주) | 88,000원 | +0.2% | — | — | — |
| 2026-11-04 | 일성타우로리딘주 | 일성아이에스(주) | 20,550원 | +1.2% | — | — | — |
| 2026-11-03 | 디쿠아론점안액5%(디쿠아포솔나트륨)(1회용) | 삼천당제약(주) | 171,400원 | +4.4% | — | — | — |
| 2026-11-03 | 동성미녹시딜정5밀리그램 | 동성제약(주) | 1,085원 | −0.9% | — | — | — |
| 2026-11-03 | 판디자임정 | (주)동구바이오제약 | 3,350원 | +1.0% | — | — | — |
| 2026-11-03 | 징크케이주(황산아연수화물) | 광동제약(주) | 6,250원 | +0.3% | — | — | — |
| 2026-10-30 | 스티렌큐정(애엽95%에탄올연조엑스(20→1)) | 동아에스티(주) | 33,850원 | +0.6% | — | — | — |
| 2026-10-30 | 셀레업정 | (주)바스칸바이오제약 | 3,215원 | +11.5% | — | — | — |
| 2026-10-30 | 팜젠아시클로버연고(수출명:파시버연고) | (주)팜젠사이언스 | 2,765원 | +9.4% | — | — | — |
| 2026-10-30 | 슈가엠파정5/25밀리그램(에보글립틴,엠파글리플로진) | 동아에스티(주) | 33,850원 | +0.6% | — | — | — |
| 2026-10-30 | 슈가엠파정5/10밀리그램(에보글립틴,엠파글리플로진) | 동아에스티(주) | 33,850원 | +0.6% | — | — | — |
| 2026-10-29 | 헌터라제아이씨브이주(이두설파제 베타)희귀 | (주)녹십자 | 132,000원 | +1.5% | — | — | — |
| 2026-10-29 | 프란피드건조시럽(프란루카스트수화물) | 동국제약(주) | 23,900원 | 0.0% | — | — | — |
| 2026-10-29 | 에치코연질캡슐 | (주)서흥 | 17,980원 | −10.6% | — | — | — |
| 2026-10-29 | 프란큐건조시럽(프란루카스트수화물) | 삼천당제약(주) | 188,600원 | −5.1% | — | — | — |
| 2026-10-27 | 오메코프에프정 | (주)에이프로젠바이오로직스 | 1,387원 | −5.8% | — | — | — |
| 2026-10-26 | 일펜싹정 | 일양약품(주) | 7,090원 | −6.1% | — | — | — |
| 2026-10-26 | 메트란캡슐500마이크로그램(메코발라민)(수출용) | 대원제약(주) | 7,640원 | +2.2% | — | — | — |
| 2026-10-26 | 종근당토피라메이트서방정100밀리그램 | (주)종근당 | 61,900원 | −1.0% | — | — | — |
| 2026-10-23 | 도나펜연질캡슐 | (주)서흥 | 18,130원 | −11.4% | — | — | — |
| 2026-10-23 | 유티프씨주(장티푸스 정제 브이아이 다당류디프테리아 CRM197단백 접합 백신)(수출용) | (주)유바이오로직스 | 7,330원 | +9.1% | — | — | — |
| 2026-10-23 | 광동테고프라잔정50밀리그램 | 광동제약(주) | 6,590원 | −4.9% | — | — | — |
| 2026-10-23 | 광동테고프라잔정25밀리그램 | 광동제약(주) | 6,590원 | −4.9% | — | — | — |
| 2026-10-22 | 바스필구강용해필름20밀리그램(타다라필) | (주)바스칸바이오제약 | 3,595원 | −0.3% | — | — | — |
| 2026-10-22 | 동성피나스테리드정 | 동성제약(주) | 1,260원 | −14.7% | — | — | — |
| 2026-10-22 | 라코주(라코사미드) | 명인제약(주) | 41,150원 | +1.6% | — | — | — |
| 2026-10-21 | 스피롱프로액 | 삼성제약(주) | 1,295원 | +2.5% | — | — | — |
| 2026-10-20 | 프란루건조시럽(프란루카스트수화물(미분화)) | (주)팜젠사이언스 | 2,780원 | +8.8% | — | — | — |
| 2026-10-19 | 액티코즈정 | 신일제약(주) | 6,410원 | +2.0% | — | — | — |
| 2026-10-19 | 콩프로정2.5밀리그램(비소프롤롤푸마르산염) | (주)대웅제약 | 107,800원 | −5.5% | — | — | — |
| 2026-10-16 | 미네파티주 | 광동제약(주) | 6,870원 | −8.7% | — | — | — |
| 2026-10-15 | 세티프리정(세티리진염산염) | (주)테라젠이텍스 | 2,000원 | +2.5% | +10.5%p | — | — |
국내 스폰서 임상
최근 14일 갱신 · 중재 2·3상| 갱신일 | 스폰서 | 임상 | 단계 | 상태 | 1차 완료(예정) | 적응증 | 중재 |
|---|---|---|---|---|---|---|---|
| 2026-11-13 | GC녹십자 · KOSPI 006280 | Phase 2 Study of GC4006A in Healthy Adults NCT07936188 · 등록 210명 | 2상 | 초청 등록신규 | 2027-10 | Covid-19 Prevention | GC4006A, GC4006A, COMIRNATY |
| 2026-11-09 | 엘레바(HLB 자회사) | A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820 · 등록 30명 | 2상 | 모집 중 | 2027-09 | FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult | Lirafugratinib |
| 2026-11-06 | SK바이오팜 · KOSPI 326030 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults NCT05219617 · 등록 252명 | 3상 | 모집 중 | 2027-02 | Seizures, Lennox Gastaut Syndrome | Carisbamate |
미국 · 글로벌
FDA 승인 · 글로벌 스폰서 임상 · 자문위FDA 최근 승인
OPENFDA무엇에 쓰는 약인지는 FDA 라벨이 공개되면 붙어요
- 11월 9일
- 11월 9일
- 10월 27일
- 10월 22일
- 10월 22일
- 10월 22일
- 10월 20일
- 10월 19일
- 10월 19일
- 10월 9일
- 9월 28일
- 9월 25일
- 9월 25일
- 9월 25일
- 9월 25일
- 9월 23일
- 9월 23일ONSWIK KWIKPEN (INSULIN EFSITORA ALFA-GOBE)ELI LILLY AND CO
AI 요약성인 제2형 당뇨병의 혈당 조절을 돕는 장시간 작용 인슐린 주사제
BLA761408INJECTABLE - 9월 22일
새 제형·조합·제조소 승인 10건 더 보기
- 11월 9일
- 10월 29일
- 10월 16일
- 10월 16일BRYTLY (APRACLONIDINE HYDROCHLORIDE)ALCON LABS INC
AI 요약눈의 가벼운 자극으로 생긴 충혈을 완화하는 점안제
NDA220341SOLUTION/DROPS - 10월 15일
- 10월 9일
- 10월 8일
- 10월 8일
- 10월 1일
- 9월 25일
더 보기: 글로벌 스폰서 임상 · FDA 자문위 공고글로벌 바이오 더 보기글로벌 스폰서 임상 · FDA 자문위 공고
글로벌 스폰서 임상
최근 14일 갱신 · 중재 2·3상| 갱신일 | 스폰서 | 임상 | 단계 | 상태 | 1차 완료(예정) | 적응증 | 중재 |
|---|---|---|---|---|---|---|---|
| 2026-11-16 | BMS · NYSE BMY | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies NCT07939815 · 등록 171명 | 1·2상 | 모집 예정 | 2029-12-29 | Advanced Solid Malignancies | BMS-986548, Cetuximab |
| 2026-11-16 | 노바티스 · NYSE NVS | A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction NCT07938411 · 등록 10000명 | 3상 | 모집 예정 | 2030-10-22 | Myocardial Infarction | Pacibekitug, Placebo |
| 2026-11-16 | 로슈 · SIX ROG | A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS) NCT07937852 · 등록 1800명 | 3상 | 모집 예정 | 2029-11-30 | Multiple Sclerosis | Fenebrutinib |
| 2026-11-16 | 사노피 · NASDAQ SNY | Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability NCT07923305 · 등록 96명 | 2·3상 | 모집 예정신규 | 2035-05-10 | Immunodeficiency Common Variable | rilzabrutinib, placebo |
| 2026-11-16 | 머크(MSD) · NYSE MRK | A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) NCT07895524 · 등록 60명 | 2상 | 모집 예정 | 2027-10-19 | Rheumatoid Arthritis | MK-8690, Placebo, Methotrexate (MTX) |
| 2026-11-16 | 머크(MSD) · NYSE MRK | Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) NCT07874815 · 등록 2136명 | 3상 | 모집 중신규 | 2029-04-29 | Pulmonary Disease, Chronic Obstructive | Ensifentrine, Placebo, Standard of Care (SOC) |
| 2026-11-16 | 머크(MSD) · NYSE MRK | A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) NCT07867938 · 등록 158명 | 2상 | 모집 중신규 | 2029-10-05 | Pulmonary Sarcoidosis | Tulisokibart, Placebo, Background prednisone therapy |
| 2026-11-16 | 로슈 · SIX ROG | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease NCT07843472 · 등록 2500명 | 3상 | 모집 중 | 2030-07-28 | Obesity or Overweight, Cardiovascular Disease | Petrelintide, Placebo |
| 2026-11-16 | 머크(MSD) · NYSE MRK | A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) NCT07839585 · 등록 352명 | 3상 | 모집 예정 | 2030-01-08 | Pulmonary Hypertension | Sotatercept, Placebo |
| 2026-11-16 | 머크(MSD) · NYSE MRK | A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) NCT07785609 · 등록 200명 | 2상 | 모집 중 | 2031-09-30 | Advanced Solid Tumors, Malignant Neoplasm | MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist |
| 2026-11-16 | GSK · NYSE GSK | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) NCT07782957 · 등록 218명 | 3상 | 모집 중 | 2029-03-06 | Nasal Polyps | GSK5784283, Placebo, Standard of Care |
| 2026-11-16 | 로슈 · SIX ROG | Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease NCT07781657 · 등록 450명 | 2상 | 모집 중신규 | 2029-11-01 | Alzheimer's Disease | RO7568282, Placebo |
| 2026-11-16 | 로슈 · SIX ROG | Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease NCT07781644 · 등록 474명 | 2상 | 모집 중신규 | 2028-12-15 | Parkinson's Disease | RO7568282, Placebo |
| 2026-11-16 | GSK · NYSE GSK | A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer NCT07740720 · 등록 100명 | 3상 | 모집 예정 | 2030-03-13 | Neoplasms, Rectal | Dostarlimab |
| 2026-11-16 | 로슈 · SIX ROG | A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis NCT07598396 · 등록 30명PubMed · 논문 1건 — Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. (Lupus science & medicine, 2026 Jun 17) | 2상 | 모집 중 | 2028-08-11 | Lupus, Systemic Lupus Erythematosus, Lupus Nephritis | Mosunetuzumab |
| 2026-11-16 | 노바티스 · NYSE NVS | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. NCT07543120 · 등록 323명 | 2상 | 모집 중 | 2031-05-07 | Hypertension (HTN) | QCZ484 |
| 2026-11-16 | 머크(MSD) · NYSE MRK | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) NCT07513376 · 등록 876명 | 3상 | 모집 중 | 2034-08-22 | Non-small Cell Lung Cancer | Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo |
| 2026-11-16 | 머크(MSD) · NYSE MRK | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827 · 등록 400명 | 3상 | 모집 중 | 2039-10-26 | Non-small Cell Lung Cancer | Calderasib, MK-3475A, Placebo |
| 2026-11-16 | 다케다 · NYSE TAK | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis NCT07250802 · 등록 210명 | 3상 | 모집 중 | 2034-07-03 | Plaque Psoriasis | Zasocitinib, Placebo, Zasocitinib |
| 2026-11-16 | 암젠 · NASDAQ AMGN | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD NCT07222553 · 등록 15명 | 2상 | 모집 중신규 | 2031-06-10 | Immunoglobulin G4-related Disease | Inebilizumab |
| 2026-11-16 | 노보 노디스크 · NYSE NVO | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide NCT07220759 · 등록 330명 | 3상 | 진행 중(모집 종료) | 2027-05-12 | Overweight, Obesity, Type 2 Diabetes | Cagrilintide, Placebo (matched to Cagrilintide) |
| 2026-11-16 | GSK · NYSE GSK | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors NCT07213609 · 등록 47명 | 1·2상 | 모집 중 | 2028-09-28 | Neoplasms, Colorectal, Neoplasms | GSK5460025 |
| 2026-11-16 | 로슈 · SIX ROG | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies NCT07177352 · 등록 80000명 | 3상 | 모집 중 | 2035-07-31 | Alzheimers Disease | No Intervention |
| 2026-11-16 | 암젠 · NASDAQ AMGN | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events NCT07136012 · 등록 11000명 | 3상 | 모집 중 | 2031-10-20 | Cardiovascular Disease | Olpasiran, Placebo |
| 2026-11-16 | 로슈 · SIX ROG | A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease NCT06998524 · 등록 75명 | 3상 | 모집 중 | 2027-10-06 | Von Willebrand Disease, Type 3 | Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates |
| 2026-11-16 | 아스트라제네카 · NASDAQ AZN | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · 등록 600명 | 3상 | 모집 중 | 2029-01-19 | Endometrial Cancer | Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab |
| 2026-11-16 | 로슈 · SIX ROG | Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033 · 등록 130명 | 2상 | 모집 중 | 2029-07-31 | Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | Obinutuzumab, Glofitamab, Gemcitabine |
| 2026-11-16 | 머크(MSD) · NYSE MRK | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) NCT06686394 · 등록 181명 | 1·2상 | 모집 중 | 2032-08-02 | Breast Neoplasms, Breast Cancer | Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar |
| 2026-11-16 | 노보 노디스크 · NYSE NVO | Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents NCT06588504 · 등록 38명 | 3상 | 완료결과 게시완료 | 2025-07-20 | Diabetes Mellitus, Type 1 | Dasiglucagon, Glucagon |
| 2026-11-16 | 아스트라제네카 · NASDAQ AZN | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) NCT05925803 · 등록 314명PubMed · 논문 1건 — Systemic sclerosis: pathogenic mechanisms and their implications for treatment. (Seminars in immunopathology, 2025 Nov 11) | 3상 | 진행 중(모집 종료) | 2027-01-06 | Systemic Sclerosis, Scleroderma | Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) |
| 2026-11-16 | 아스트라제네카 · NASDAQ AZN | A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma NCT05692180 · 등록 94명 | 3상 | 진행 중(모집 종료) | 2026-12-23 | Asthma | Benralizumab, Placebo |
| 2026-11-16 | 화이자 · NYSE PFE | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · 등록 400명 | 3상 | 진행 중(모집 종료) | 2027-12-31 | Colorectal Neoplasms | tucatinib, trastuzumab, bevacizumab |
| 2026-11-16 | 노바티스 · NYSE NVS | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease NCT05030428 · 등록 17004명 | 3상 | 진행 중(모집 종료) | 2027-05-10 | Atherosclerotic Cardiovascular Disease | Inclisiran sodium 300 mg, Placebo |
| 2026-11-16 | 노바티스 · NYSE NVS | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC NCT04952753 · 등록 202명 | 2상 | 조기 종료결과 게시중단사유: The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose. | 2025-01-20 | Metastatic Colorectal Cancer | NIS793, Bevacizumab, Modified FOLFOX6 |
| 2026-11-16 | 노보 노디스크 · NYSE NVO | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity NCT04775082 · 등록 82명 | 3상 | 진행 중(모집 종료)결과 게시 | 2023-08-01 | Obesity | Liraglutide, Placebo |
| 2026-11-16 | 애브비 · NYSE ABBV | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) NCT04567550 · 등록 139명 | 2상 | 완료완료 | 2026-06-18 | Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME) | ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3 |
| 2026-11-16 | 아스트라제네카 · NASDAQ AZN | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy NCT03534453 · 등록 225명 | 3상 | 완료결과 게시완료 | 2025-01-27 | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive | Olaparib 300mg tablets |
| 2026-11-13 | 일라이 릴리 · NYSE LLY | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer NCT07935317 · 등록 120명 | 2상 | 모집 예정 | 2027-12 | Breast Neoplasms | Abemaciclib, Tersolisib, Letrozole |
| 2026-11-13 | 사노피 · NASDAQ SNY | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older NCT07890454 · 등록 6000명 | 3상 | 모집 중신규 | 2027-12-28 | Immunization, Healthy Volunteers, COVID-19 Immunization | IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination |
| 2026-11-13 | 다이이찌산쿄 · TSE 4568 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) NCT07791732 · 등록 600명 | 3상 | 모집 예정 | 2029-07-01 | Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer | R-DXd, Bevacizumab |
| 2026-11-13 | 아스트라제네카 · NASDAQ AZN | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus NCT07430306 · 등록 245명 | 3상 | 모집 중 | 2029-01-26 | Systemic Lupus Erythematosus | Anifrolumab |
| 2026-11-13 | 노바티스 · NYSE NVS | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) NCT07190300 · 등록 181명 | 1·2상 | 모집 중 | 2032-08-02 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Tulmimetostat, Darolutamide, Abiraterone |
| 2026-11-13 | 아스트라제네카 · NASDAQ AZN | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia NCT07109219 · 등록 83명 | 1·2상 | 모집 중 | 2028-10-11 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | AZD4512 monotherapy |
| 2026-11-13 | 사노피 · NASDAQ SNY | A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes NCT07088068 · 등록 723명 | 3상 | 모집 중 | 2028-06-06 | Type 1 Diabetes Mellitus | Teplizumab, Placebo |
| 2026-11-13 | BMS · NYSE BMY | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · 등록 590명 | 2·3상 | 모집 중 | 2031-08-12 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | BMS-986504, Pembrolizumab, Placebo |
| 2026-11-13 | 노바티스 · NYSE NVS | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT07047118 · 등록 138명 | 2상 | 진행 중(모집 종료) | 2027-07-16 | Prostatic Cancer, Castration-Resistant | JSB462, AAA617 |
| 2026-11-13 | 노바티스 · NYSE NVS | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) NCT06991556 · 등록 168명 | 2상 | 진행 중(모집 종료) | 2026-12-03 | Metastatic Hormone-sensitive Prostate Cancer | JSB462, Abiraterone, Enzalutamide |
| 2026-11-13 | 아스트라제네카 · NASDAQ AZN | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia NCT06834932 · 등록 432명 | 2·3상 | 진행 중(모집 종료) | 2027-02-22 | Dyslipidaemia | Placebo, Rosuvastatin Dose 1, Rosuvastatin dose 2 |
| 2026-11-13 | GSK · NYSE GSK | A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease NCT06613698 · 등록 350명 | 2상 | 모집 중 | 2027-11-26 | Liver Diseases, Alcoholic | GSK4532990, Placebo |
| 2026-11-13 | 일라이 릴리 · NYSE LLY | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) NCT06297603 · 등록 320명 | 3상 | 진행 중(모집 종료) | 2026-10-26 | Type 2 Diabetes | Retatrutide, Placebo |
| 2026-11-13 | 리제네론 · NASDAQ REGN | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · 등록 733명 | 3상 | 진행 중(모집 종료) | 2029-07-29 | Follicular Lymphoma (FL) | Odronextamab, Rituximab, Cyclophosphamide |
| 2026-11-13 | 암젠 · NASDAQ AMGN | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) NCT05920356 · 등록 750명 | 3상 | 모집 중 | 2027-06-30 | Non-Small Cell Lung Cancer (NSCLC) | Sotorasib, Pembrolizumab |
| 2026-11-13 | 애브비 · NYSE ABBV | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy NCT05889182 · 등록 1328명 | 3상 | 진행 중(모집 종료) | 2028-08 | Hidradenitis Suppurativa | Upadacitinib, Placebo |
| 2026-11-13 | 노바티스 · NYSE NVS | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081 · 등록 1466명 | 3상 | 진행 중(모집 종료) | 2029-09-07 | Early Breast Cancer | Ribociclib, Letrozole, Ansastrozole |
| 2026-11-13 | 아스트라제네카 · NASDAQ AZN | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT05057494 · 등록 607명PubMed · 논문 1건 — MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. (Future oncology (London, England), 2022 Oct) | 3상 | 진행 중(모집 종료) | 2027-07-15 | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Acalabrutinib, Venetoclax, Obinutuzumab |
| 2026-11-13 | 얀센(J&J) · NYSE JNJ | A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy NCT04513912 · 등록 757명 | 3상 | 완료결과 게시완료 | 2023-10-03 | Depressive Disorder, Major | Seltorexant, Matching placebo to Seltorexant, Quetiapine XR |
| 2026-11-13 | GSK · NYSE GSK | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT04246047 · 등록 494명PubMed · 논문 5건 — Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. (PharmacoEconomics - open, 2026 Sep 11) | 3상 | 진행 중(모집 종료) | 2023-10-02 | Multiple Myeloma | Belantamab mafodotin, Daratumumab, Bortezomib |
| 2026-11-13 | 애브비 · NYSE ABBV | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension NCT03850782 · 등록 515명PubMed · 논문 1건 — Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON). (Drugs, 2025 Apr) | 3상 | 완료결과 게시완료 | 2025-08-08 | Open-Angle Glaucoma, Ocular Hypertension | Bimatoprost (SR) |
| 2026-11-12 | 애브비 · NYSE ABBV | A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis NCT07933536 · 등록 105명 | 2상 | 모집 예정 | 2028-12 | Moderate to Severe Psoriasis | Risankizumab, ABBV-295, ABBV-295 Placebo |
| 2026-11-12 | 리제네론 · NASDAQ REGN | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) NCT07933328 · 등록 120명 | 2상 | 모집 예정 | 2029-05-07 | Alcohol-Associated Liver Disease, ALD | ALN-CIDEB, Placebo |
| 2026-11-12 | 애브비 · NYSE ABBV | A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. NCT07933211 · 등록 580명 | 2·3상 | 모집 예정 | 2035-06 | Systemic Sclerosis | ABBV-722, Upadacitinib, Placebo for ABBV-722 |
| 2026-11-12 | 화이자 · NYSE PFE | The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight NCT07932925 · 등록 900명 | 3상 | 모집 예정신규 | 2028-10-13 | Urinary Incontinence, Stress, Overweight and/or Obesity | Berobenatide, Placebo |
| 2026-11-12 | 노보 노디스크 · NYSE NVO | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both NCT07931599 · 등록 1060명 | 3상 | 모집 예정신규 | 2028-07-24 | Diabetes Mellitus, Type 2 | Zenagamtide, Semaglutide, Placebo zenagamtide |
| 2026-11-12 | 노보 노디스크 · NYSE NVO | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both NCT07931573 · 등록 1200명 | 3상 | 모집 예정신규 | 2028-07-04 | Type 2 Diabetes | Zenagamtide, Semaglutide, Placebo |
| 2026-11-12 | 노보 노디스크 · NYSE NVO | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both NCT07931547 · 등록 450명 | 3상 | 모집 예정신규 | 2028-07-31 | Type 2 Diabetes, Chronic Kidney Disease | Placebo, Zenagamtide |
| 2026-11-12 | 노보 노디스크 · NYSE NVO | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise NCT07931495 · 등록 200명 | 3상 | 모집 예정신규 | 2028-06-05 | Diabetes Mellitus, Type 2 | Zenagamtide, Placebo |
| 2026-11-12 | 사노피 · NASDAQ SNY | A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis NCT07930624 · 등록 2500명 | 3상 | 모집 예정 | 2031-05-16 | Multiple Sclerosis | Frexalimab, Frexalimab, Frexalimab Placebo |
| 2026-11-12 | 화이자 · NYSE PFE | A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults NCT07794748 · 등록 4701명 | 3상 | 진행 중(모집 종료) | 2027-04-26 | Pneumococcal Disease | PG4 Multivalent Vaccine, PG4 Multivalent Vaccine, PG4 Multivalent Vaccine |
| 2026-11-12 | GSK · NYSE GSK | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) NCT07780669 · 등록 624명 | 3상 | 모집 중 | 2029-07-20 | Pulmonary Disease, Chronic Obstructive | GSK5784283, Placebo, Standard of care |
| 2026-11-12 | GSK · NYSE GSK | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) NCT07780656 · 등록 624명 | 3상 | 모집 중 | 2029-07-20 | Pulmonary Disease, Chronic Obstructive | GSK5784283, Placebo, Standard of care |
| 2026-11-12 | 화이자 · NYSE PFE | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema NCT07765888 · 등록 375명 | 3상 | 모집 중 | 2028-03-10 | Atopic Dermatitis | Tilrekimig, Placebo |
| 2026-11-12 | 암젠 · NASDAQ AMGN | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration NCT07614776 · 등록 304명 | 3상 | 모집 중 | 2027-07-31 | Neovascular Age-related Macular Degeneration, nAMD | ABP 938 8 mg, Aflibercept (US) 8 mg |
| 2026-11-12 | 리제네론 · NASDAQ REGN | A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) NCT07559513 · 등록 18명 | 3상 | 모집 예정 | 2030-07-08 | Fibrodysplasia Ossificans Progressiva, FOP | garetosmab |
| 2026-11-12 | BMS · NYSE BMY | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) NCT07288567 · 등록 166명 | 3상 | 모집 중 | 2029-12-18 | Schizophrenia | KarXT, KarXT Matching Placebo |
| 2026-11-12 | 다케다 · NYSE TAK | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058 · 등록 1182명 | 3상 | 모집 중 | 2029-12-18 | Psoriatic Arthritis | Zasocitinib |
| 2026-11-12 | 리제네론 · NASDAQ REGN | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults NCT07220772 · 등록 4명 | 3상 | 모집 중 | 2027-06-18 | Monogenic Obesity | Mibavademab |
| 2026-11-12 | 사노피 · NASDAQ SNY | A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission NCT07156175 · 등록 60명 | 2상 | 진행 중(모집 종료) | 2027-04-08 | Microscopic Colitis | SAR444336, Placebo |
| 2026-11-12 | BMS · NYSE BMY | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080 · 등록 661명 | 2·3상 | 모집 중 | 2028-12-15 | Non-Small Cell Lung Cancer | Iza-bren, Carboplatin, Cisplatin |
| 2026-11-12 | 사노피 · NASDAQ SNY | Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment NCT07007962 · 등록 60명PubMed · 논문 1건 — Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways. (Expert review of hematology, 2026 Jul) | 3상 | 모집 중 | 2027-11-05 | Immune Thrombocytopenia | rilzabrutinib |
| 2026-11-12 | BMS · NYSE BMY | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) NCT06937229 · 등록 650명 | 3상 | 모집 중 | 2029-06-22 | Alzheimer Disease, Agitation | KarXT, KarX-EC |
| 2026-11-12 | 바이엘 · XETRA BAYN | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors NCT06914128 · 등록 450명 | 1·2상 | 모집 중 | 2029-06-18 | MTAP-deleted Solid Tumors | BAY 3713372 |
| 2026-11-12 | 화이자 · NYSE PFE | A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema NCT06807268 · 등록 151명 | 3상 | 진행 중(모집 종료) | 2027-05-02 | Eczema | Abrocitinib, Placebo |
| 2026-11-12 | 화이자 · NYSE PFE | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. NCT06758401 · 등록 714명PubMed · 논문 1건 — Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. (Future oncology (London, England), 2025 Dec) | 3상 | 모집 중 | 2028-09-05 | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) | Sigvotatug Vedotin, Pembrolizumab |
| 2026-11-12 | 얀센(J&J) · NYSE JNJ | Nipocalimab in Moderate to Severe Sjogren's Disease NCT06741969 · 등록 655명 | 3상 | 진행 중(모집 종료) | 2027-02-04 | Sjogrens Syndrome | Nipocalimab, Placebo, Standard of care treatment |
| 2026-11-12 | 다케다 · NYSE TAK | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines NCT06671483 · 등록 1583명 | 3상 | 진행 중(모집 종료) | 2027-05-18 | Psoriatic Arthritis | Zasocitinib, Active Comparator, Placebo |
| 2026-11-12 | 사노피 · NASDAQ SNY | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT06500702 · 등록 84명PubMed · 논문 1건 — What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? (Journal of the American Society of Nephrology : JASN, 2025 Feb 3) | 2상 | 모집 중 | 2026-12-23 | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | frexalimab, brivekimig, rilzabrutinib |
| 2026-11-12 | 리제네론 · NASDAQ REGN | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation NCT06299098 · 등록 1005명PubMed · 논문 1건 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial. (Lancet (London, England), 2026 Nov 11) | 2상 | 완료완료 | 2026-06-16 | Obesity | Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab |
| 2026-11-12 | 바이엘 · XETRA BAYN | A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies NCT06246643 · 등록 13명 | 2상 | 진행 중(모집 종료) | 2028-04-27 | Solid Malignant Tumors | Regorafenib (Stivarga, BAY73-4506) |
| 2026-11-12 | 일라이 릴리 · NYSE LLY | A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis NCT06220669 · 등록 65명 | 2상 | 조기 종료결과 게시중단사유: The interim analysis data failed to demonstrate the intended treatment effect. | 2025-10-18 | Multiple Sclerosis | LY3541860, Placebo |
| 2026-11-12 | 다케다 · NYSE TAK | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) NCT06165341 · 등록 50명 | 3상 | 모집 중 | 2028-08-26 | Alpha1-Antitrypsin Deficiency | Fazirsiran Injection, Placebo |
| 2026-11-12 | 화이자 · NYSE PFE | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575 · 등록 492명 | 3상 | 모집 중 | 2026-08-26 | Multiple Myeloma | Elranatamab, Elotuzumab, Pomalidomide |
| 2026-11-12 | 리제네론 · NASDAQ REGN | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286 · 등록 580명 | 3상 | 모집 중 | 2031-04-30 | Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Odronextamab, Lenalidomide, Rituximab |
| 2026-11-12 | BMS · NYSE BMY | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) NCT05980949 · 등록 1000명 | 3상 | 모집 중 | 2027-09-07 | Psychosis Associated With Alzheimer's Disease | KarXT |
| 2026-11-12 | 다케다 · NYSE TAK | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease NCT05899673 · 등록 200명 | 3상 | 진행 중(모집 종료) | 2033-05-02 | Alpha1-Antitrypsin Deficiency | Fazirsiran Injection |
| 2026-11-12 | 화이자 · NYSE PFE | A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy. NCT05689164 · 등록 7명 | 3상 | 조기 종료결과 게시중단사유: All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003 | 2025-09-24 | Duchenne Muscular Dystrophy | fordadistrogene movaparvovec |
| 2026-11-12 | GSK · NYSE GSK | Phase 2b Study of GSK4532990 in Adults With NASH NCT05583344 · 등록 284명 | 2상 | 완료완료 | 2026-01-31 | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | GSK4532990, Placebo |
| 2026-11-12 | 일라이 릴리 · NYSE LLY | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity NCT05556512 · 등록 15374명PubMed · 논문 1건 — Hypertension in young adults with obesity: new mechanisms and therapeutic options. (Polish archives of internal medicine, 2026 Feb 26) | 3상 | 진행 중(모집 종료) | 2027-10 | Obesity, Overweight | Tirzepatide, Placebo |
| 2026-11-12 | 리제네론 · NASDAQ REGN | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition NCT05519475 · 등록 120명 | 2상 | 진행 중(모집 종료) | 2028-04-27 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | ALN-HSD, Placebo |
| 2026-11-12 | 바이엘 · XETRA BAYN | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172 · 등록 430명PubMed · 논문 1건 — Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. (The New England journal of medicine, 2025 Nov 6) | 1·2상 | 모집 중 | 2028-12-01 | Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation | BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2 |
| 2026-11-12 | BMS · NYSE BMY | A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) NCT04446650 · 등록 31명 | 1·2상 | 완료완료 | 2023-10-05 | Primary Myelofibrosis | Fedratinib |
| 2026-11-12 | 리제네론 · NASDAQ REGN | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT03088540 · 등록 712명PubMed · 논문 6건 — Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. (Cancer, 2026 Mar 15) | 3상 | 완료완료 | 2025-04-18 | Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma | Pemetrexed, Paclitaxel, Gemcitabine |
| 2026-11-12 | 길리어드 · NASDAQ GILD | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection NCT02932150 · 등록 150명 | 2상 | 진행 중(모집 종료) | 2026-10-27 | Chronic Hepatitis B | TAF, Placebo |
| 2026-11-10 | 일라이 릴리 · NYSE LLY | A Study of Brenipatide in Participants With Major Depressive Disorder NCT07928245 · 등록 330명 | 2상 | 모집 예정신규 | 2028-05 | Major Depressive Disorder | Brenipatide, Placebo |
| 2026-11-10 | 애브비 · NYSE ABBV | Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis NCT07904754 · 등록 250명 | 2상 | 모집 예정 | 2029-07 | Rheumatoid Arthritis | ABBV-722, Upadacitinib |
| 2026-11-10 | 다이이찌산쿄 · TSE 4568 | A Study of DS-3939a in Participants With Solid Tumors NCT07739966 · 등록 400명 | 1·2상 | 모집 중 | 2030-07-31 | Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | DS-3939a, Pembrolizumab, Carboplatin |
| 2026-11-10 | 길리어드 · NASDAQ GILD | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment NCT07708727 · 등록 700명 | 2·3상 | 모집 중 | 2030-10 | HIV-1-infection | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet |
| 2026-11-10 | 길리어드 · NASDAQ GILD | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 NCT07645287 · 등록 175명 | 2상 | 모집 중 | 2027-08 | HIV-1-infection | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet |
| 2026-11-10 | 길리어드 · NASDAQ GILD | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas NCT07546812 · 등록 120명 | 2상 | 진행 중(모집 종료) | 2030-01 | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma | Denikitug, Nivolumab, Ramucirumab |
| 2026-11-10 | 노보 노디스크 · NYSE NVO | AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight NCT07400107 · 등록 985명 | 3상 | 진행 중(모집 종료) | 2028-12-19 | Obesity, Overweight, Diabetes Mellitus, Type 2 | NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111) |
| 2026-11-10 | BMS · NYSE BMY | A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism NCT07284745 · 등록 176명 | 3상 | 모집 중 | 2029-08-06 | Irritability Associated With Autism Spectrum Disorder | KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo |
| 2026-11-10 | 일라이 릴리 · NYSE LLY | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · 등록 250명 | 3상 | 진행 중(모집 종료) | 2027-06 | Obesity, Overweight | Retatrutide, Placebo |
| 2026-11-10 | 사노피 · NASDAQ SNY | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan NCT07216079 · 등록 3명 | 3상 | 진행 중(모집 종료) | 2026-11-25 | Immune Thrombocytopenia | rilzabrutinib |
| 2026-11-10 | 다이이찌산쿄 · TSE 4568 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · 등록 1233명PubMed · 논문 1건 — TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. (Future oncology (London, England), 2024) | 3상 | 진행 중(모집 종료) | 2029-05-11 | Metastatic Non Small Cell Lung Cancer | Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed |
| 2026-11-10 | 다케다 · NYSE TAK | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet NCT04530123 · 등록 102명 | 2상 | 완료완료 | 2025-12-09 | Celiac Disease | Placebo, TAK-101, Gluten |
| 2026-11-10 | 다케다 · NYSE TAK | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma NCT02979522 · 등록 59명PubMed · 논문 1건 — Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens. (Journal of clinical pharmacology, 2020 Dec) | 1·2상 | 진행 중(모집 종료) | 2020-05-05 | Hodgkin Disease | Brentuximab vedotin, Doxorubicin, Vinblastine |
| 2026-11-09 | 암젠 · NASDAQ AMGN | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight NCT07871409 · 등록 230명 | 3상 | 모집 중 | 2027-06-16 | Obesity, Overweight | Maridebart cafraglutide, Autoinjector |
| 2026-11-09 | 모더나 · NASDAQ MRNA | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age NCT07808697 · 등록 300명 | 2상 | 모집 중 | 2029-08-30 | SARS-CoV-2 | mRNA-1283, mRNA-1273 |
| 2026-11-09 | 애브비 · NYSE ABBV | Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis NCT06865105 · 등록 300명 | 2상 | 모집 중 | 2029-08 | Psoriatic Arthritis | Lutikizumab, Risankizumab, ABBV-701 |
| 2026-11-09 | 일라이 릴리 · NYSE LLY | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05936151 · 등록 146명PubMed · 논문 1건 — Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026 May 29) | 2상 | 완료결과 게시완료 | 2025-10-01 | Overweight or Obesity, CKD, Type 2 Diabetes | Retatrutide, Placebo |
| 2026-11-06 | 일라이 릴리 · NYSE LLY | A Study of Bimagrumab in Participants With HFpEF NCT07920887 · 등록 540명 | 2상 | 모집 예정신규 | 2029-07 | Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction | Bimagrumab, Placebo |
| 2026-11-06 | 다케다 · NYSE TAK | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161 · 등록 324명 | 3상 | 모집 중 | 2029-12-07 | Myelofibrosis, Anemia | Placebo, Elritercept |
| 2026-11-06 | 암젠 · NASDAQ AMGN | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) NCT07575399 · 등록 300명 | 3상 | 모집 중 | 2028-01-03 | Obesity or Overweight | Maridebart Cafraglutide |
| 2026-11-06 | 암젠 · NASDAQ AMGN | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab NCT06211036 · 등록 563명PubMed · 논문 2건 — Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. (The New England journal of medicine, 2026 Oct 24) | 3상 | 진행 중(모집 종료) | 2030-04-02 | Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Tarlatamab, Durvalumab |
| 2026-11-06 | 애브비 · NYSE ABBV | A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 NCT06032546 · 등록 163명 | 2상 | 조기 종료결과 게시중단사유: Company Decision | 2025-09-22 | Human Immuno-deficiency Virus (HIV) Disease | Budigalimab, Placebo for Budigalimab, ABBV-382 |
| 2026-11-06 | 다이이찌산쿄 · TSE 4568 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) NCT04703192 · 등록 155명PubMed · 논문 1건 — Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. (The Lancet. Oncology, 2024 Dec) | 2상 | 진행 중(모집 종료) | 2023-05-10 | Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma | Valemetostat Tosylate |
| 2026-11-05 | 암젠 · NASDAQ AMGN | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes NCT07866066 · 등록 1300명 | 3상 | 모집 중 | 2028-09-06 | Diabetes Mellitus, Type 2 | Maridebart cafraglutide, Semaglutide |
| 2026-11-05 | 바이엘 · XETRA BAYN | A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. NCT07450599 · 등록 250명 | 2상 | 모집 중 | 2028-10-15 | High-risk Localized Prostate Cancer | Darolutamide, ADT |
| 2026-11-05 | 길리어드 · NASDAQ GILD | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy NCT06333808 · 등록 577명PubMed · 논문 2건 — Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. (The lancet. HIV, 2026 Aug) | 3상 | 진행 중(모집 종료)결과 게시 | 2025-10-27 | HIV-1-infection | Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF |
| 2026-11-05 | 길리어드 · NASDAQ GILD | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) NCT05502341 · 등록 689명PubMed · 논문 2건 — Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. (Lancet (London, England), 2026 Mar 28) | 2·3상 | 진행 중(모집 종료)결과 게시 | 2025-09-29 | HIV-1-infection | Bictegravir, Lenacapavir, BIC/LEN FDC |
| 2026-11-05 | 얀센(J&J) · NYSE JNJ | A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) NCT04968912 · 등록 163명PubMed · 논문 2건 — Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. (Human vaccines & immunotherapeutics, 2026 Dec) | 2상 | 완료결과 게시완료 | 2023-10-23 | Sjogren's Syndrome | Placebo, Nipocalimab, Standard of Care Treatment |
| 2026-11-05 | 얀센(J&J) · NYSE JNJ | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis NCT04951622 · 등록 199명PubMed · 논문 5건 — Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. (Human vaccines & immunotherapeutics, 2026 Dec) | 3상 | 모집 중 | 2023-11-17 | Myasthenia Gravis | Nipocalimab, Placebo, Nipocalimab SC-LIV |
| 2026-11-05 | 얀센(J&J) · NYSE JNJ | A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease NCT04619420 · 등록 523명PubMed · 논문 1건 — Mechanistic Population Pharmacokinetic-Pharmacodynamic Model of the Tau-Targeted Antibody Posdinemab in Healthy Participants and Participants with Alzheimer's Disease. (Clinical pharmacology and therapeutics, 2026 Apr) | 2상 | 조기 종료결과 게시중단사유: Posdinemab did not achieve statistical significance in slowing clinical decline | 2025-10-17 | Alzheimer Disease, Cognitive Dysfunction, Dementia | JNJ-63733657, Placebo |
| 2026-11-04 | 바이엘 · XETRA BAYN | A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277 · 등록 444명 | 3상 | 모집 중 | 2027-10-28 | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Sevabertinib, Pembrolizumab, Cisplatin |
| 2026-11-04 | 얀센(J&J) · NYSE JNJ | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis NCT06143878 · 등록 774명PubMed · 논문 1건 — Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. (Lancet (London, England), 2025 Sep 27) | 3상 | 진행 중(모집 종료) | 2024-09-17 | Plaque Psoriasis | JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib |
| 2026-11-04 | 길리어드 · NASDAQ GILD | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) NCT05633654 · 등록 1514명PubMed · 논문 1건 — OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. (Future oncology (London, England), 2024) | 3상 | 모집 중 | 2027-06 | Triple Negative Breast Cancer | Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine |
| 2026-11-04 | 얀센(J&J) · NYSE JNJ | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma NCT05572515 · 등록 614명PubMed · 논문 1건 — Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. (The New England journal of medicine, 2026 Jul 30) | 3상 | 진행 중(모집 종료) | 2025-10-13 | Multiple Myeloma | Teclistamab, Pomalidomide, Bortezomib |
| 2026-11-04 | 얀센(J&J) · NYSE JNJ | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure NCT04988295 · 등록 776명PubMed · 논문 1건 — Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup. (Translational lung cancer research, 2026 Sep 30) | 3상 | 진행 중(모집 종료) | 2023-07-10 | Carcinoma, Non-Small-Cell Lung | Lazertinib, Amivantamab, Pemetrexed |
| 2026-11-03 | 길리어드 · NASDAQ GILD | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC NCT06303505 · 등록 334명 | 1·2상 | 모집 중 | 2027-12 | Ovarian Cancer, Non-small Cell Lung Cancer | TUB-040, Bevacizumab |